GDMT stands for Guideline-Directed Medical Therapy, which refers to the optimal, evidence-based set of drug treatments recommended by established guidelines for chronic diseases, most prominently heart failure with reduced ejection fraction.
For heart failure with reduced ejection fraction (HFrEF), GDMT involves four main classes of medications:
Renin-angiotensin system inhibitors (ACE inhibitors, ARBs, ARNis) Beta-blockers Mineralocorticoid receptor antagonists (MRAs) Sodium-glucose cotransporter-2 (SGLT2) inhibitors.
Each type of drug class works to improve heart function, reduce symptoms, and decrease the risks of hospitalization and death with the best outcomes observed when all classes are used together as tolerated.
The addition of these agents, when titrated to target or maximally tolerated doses, has been shown to reduce all-cause mortality by up to 73% compared to no treatment.
Utilizing GDMT can dramatically improve quality of life, slow disease progression, and add years to life expectancy in HFrEF patients.
The application of all four pillars of GDMT has been associated with up to 74% decrease in risk of death in HFrEF patients.
The higher tolerated doses of GDMT, the greater the clinical benefit.
Guideline-directed medical therapy (GDMT) for heart failure is founded on large randomized controlled trials and meta-analyses demonstrating substantial reductions in all-cause mortality, cardiovascular death, and heart failure hospitalizations.
For a representative 70-year-old patient, quadruple therapy (ARNI, beta-blocker, MRA, SGLT2i) provides an estimated 5.3 additional life-years versus no treatment, with quintuple therapy (adding vericiguat) providing 6.0 additional life-years.
These benefits are consistent across age, sex, and racial/ethnic groups, and are supported by the most recent network meta-analyses and guideline updates.
The evidence base for heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) is less robust, but recent trials have established SGLT2 inhibitors as the only class with consistent benefit across the full spectrum of ejection fraction.
The implementation of GDMT should be rapid, with simultaneous initiation and up-titration of multiple agents as tolerated, and frequent monitoring to achieve target doses within 2–3 months of diagnosis.
Phenotype-Specific GDMT: HFrEF, HFmrEF, and HFpEF
For patients with HFrEF (LVEF ≤40%) guidelines recommend the immediate initiation of four foundational drug classes: ARNI (sacubitril/valsartan), evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), MRA (spironolactone or eplerenone), and SGLT2 inhibitor (dapagliflozin or empagliflozin).
The goal is to initiate all four agents as soon as feasible, with up-titration to target or maximally tolerated doses within 2–3 months.
The typical starting and target doses are as follows: sacubitril/valsartan 24/26 mg twice daily, titrated to 97/103 mg twice daily; carvedilol 3.125 mg twice daily, titrated to 25–50 mg twice daily; spironolactone 12.5–25 mg daily, titrated to 25–50 mg daily; dapagliflozin or empagliflozin 10 mg once daily.
Quadruple therapy reduces all-cause mortality by 61% compared to placebo, and provides an absolute gain of 5.3 life-years for a 70-year-old patient.
The addition of vericiguat, a soluble guanylate cyclase stimulator, may provide an incremental survival gain of approximately 0.7 years, but is reserved for patients with recent worsening heart failure despite optimal treatment.
Adjunctive therapies such as hydralazine/isosorbide dinitrate for Black patients with persistent symptoms, ivabradine for patients in sinus rhythm with heart rate ≥70 bpm despite beta-blocker, and digoxin are recommended for select populations.
The use of all four drug classes should be pursued unless contraindicated.
If ARNI is not tolerated, an ACE inhibitor or ARB may be substituted.
MRAs are contraindicated in patients with eGFR 5.0 mmol/L.
SGLT2 inhibitors are generally safe down to eGFR 20–25 mL/min/1.73 m², but should be avoided in patients with a history of diabetic ketoacidosis or severe hypersensitivity.
Beta-blockers should not be initiated in acutely decompensated patients, but may be continued if already prescribed.
Heart failure with mildly reduced ejection fraction (HFmrEF, LVEF 41–49%) is managed with a similar approach to HFrEF, based on post hoc analyses and meta-analyses demonstrating benefit from neurohormonal antagonists and SGLT2 inhibitors.
A Class 2a recommendation for SGLT2 inhibitors (dapagliflozin or empagliflozin 10 mg daily) in all patients with HFmrEF, and a Class 2b recommendation for ARNI, ACEi/ARB, beta-blocker, and MRA, particularly for those with LVEF at the lower end of the spectrum.
The combination of SGLT2i, ARNI, and MRA provides the greatest reduction in the risk of cardiovascular death and heart failure hospitalization, with the benefit most pronounced in HFmrEF (HR for composite outcome: 0.47, 95% CI: 0.31–0.70).
Beta-blockers and ARNI/ACEi/ARB should be titrated to the same target doses as in HFrEF, with careful monitoring for hypotension, bradycardia, and renal dysfunction.
MRAs are particularly useful in patients with poorly controlled hypertension or evidence of elevated natriuretic peptides.
Diuretics are used for symptom relief in patients with volume overload, but do not confer a mortality benefit.
For heart failure with preserved ejection fraction (HFpEF, LVEF ≥50%), the American College of Cardiology, American Heart Association, and Heart Failure Society of America recommend SGLT2 inhibitors as first-line therapy for all patients, with a Class 2a recommendation (dapagliflozin or empagliflozin 10 mg daily).
This is based on large randomized controlled trials (DELIVER, EMPEROR-Preserved) demonstrating an 18–21% reduction in the composite endpoint of heart failure hospitalization or cardiovascular death, primarily driven by reductions in heart failure hospitalizations.
The benefit is consistent across the full spectrum of ejection fraction, but is most pronounced in patients with LVEF.
Diuretics remain the only therapy with a Class I recommendation for the management of congestion in HFpEF, with the dose titrated to achieve and maintain euvolemia.
MRAs (spironolactone 25–50 mg daily) and ARNI (sacubitril/valsartan 24/26 mg to 97/103 mg twice daily) may be considered in patients with LVEF at the lower end of the preserved range (50–60%) or with high-risk features, but the strength of recommendation is lower (Class 2b).
Beta-blockers are not recommended as routine therapy for HFpEF, except for comorbid conditions such as atrial fibrillation or angina.
The following table from Cannata and McDonagh published in The New England Journal of Medicine summarizes the guideline-recommended treatments for HFpEF, including dosages, indications, and recommendation strength across major international guidelines.
Lifestyle modification, including supervised exercise training and weight loss for patients with obesity, is strongly recommended to improve functional status and quality of life.
Comorbidity management (hypertension, diabetes, atrial fibrillation, sleep apnea) is essential for optimal outcomes.
GDMT is initiated at low starting doses and titrated to target or maximally tolerated doses as rapidly as is safely possible, ideally within 2–3 months of diagnosis.
Titration intervals are typically every 1–2 weeks with monitoring of blood pressure, heart rate, renal function, serum potassium, and symptoms at each step.
Drug initiation:sacubitril/valsartan is started at 24/26 mg twice daily and increased to 49/51 mg and then 97/103 mg twice daily as tolerated; carvedilol is titrated from 3.125 mg twice daily to 25–50 mg twice daily; spironolactone from 12.5–25 mg daily to 25–50 mg daily; dapagliflozin and empagliflozin are started and maintained at 10 mg daily.
The STRONG-HF trial demonstrated that high-intensity titration of GDMT with the achieving 50% of target doses by hospital discharge and 100% by two weeks post-discharge leads to improved outcomes, including reduced heart failure readmissions and mortality.
Laboratory monitoring: renal function and electrolytes (especially potassium) at baseline, within 1–2 weeks of initiation or dose increase, and periodically thereafter.
Reassessment of ventricular function by echocardiography is recommended 3–6 months after achieving target or maximally tolerated doses to guide further management, including consideration of device therapy.
ARNI, ACEi, and ARB are generally safe down to eGFR 30 mL/min/1.73 m², with some data supporting ARNI use to eGFR as low as 20 mL/min/1.73 m².
MRAs are contraindicated in eGFR 5.0 mmol/L.
SGLT2 inhibitors are effective and safe down to eGFR 20–25 mL/min/1.73 m².
For patients with diabetes, the foundational GDMT for HFrEF should be applied as in those without diabetes, with particular emphasis on SGLT2 inhibitors for dual benefit in glycemic control and heart failure outcomes.
In older adults and those with frailty, lower starting doses and slower titration are appropriate, with a focus on tolerability and minimizing adverse effects.
Even submaximal doses confer benefit compared to no therapy.
Women and racial/ethnic minorities derive similar benefit from GDMT as men and White patients, for the composite of cardiovascular death and heart failure hospitalization in women of 0.86 for ACEi/ARB, 0.77 for ARNI, 0.67 for beta-blockers, 0.77 for MRAs, and 0.66 for SGLT2 inhibitors.
All patients, regardless of sex or race/ethnicity, should receive the full complement of GDMT, with attention to overcoming disparities in care delivery and outcomes.
In patients with heart failure with improved ejection fraction (HFimpEF), defined as prior LVEF ≤40% with subsequent normalization and symptomatic improvement, it is recommend that all classes of GDMT should be continued indefinitely to prevent relapse, except for loop diuretics, which may be reduced or discontinued if the patient is euvolemic.
The TRED-HF trial demonstrated a 40% relapse rate within six months of medication withdrawal in this population.
In advanced heart failure (NYHA class IV, inotrope/pressor dependence), de-escalation or withdrawal of ARNI/ACEi/ARB/beta-blocker may be necessary due to hypotension or renal dysfunction, but SGLT2i and MRA may be continued if tolerated.
For unique etiologies, such as cardiac amyloidosis, hypertrophic cardiomyopathy (HCM), and peripartum cardiomyopathy (PPCM), GDMT must be adapted to disease-specific pathophysiology.
In cardiac amyloidosis, standard neurohormonal antagonists are generally avoided due to risk of hypotension and poor tolerance; volume management with loop diuretics and MRAs is the mainstay, and disease-modifying therapy (tafamidis for ATTR) is recommended.
In HCM with LVEF
In PPCM, neurohormonal antagonists are contraindicated during pregnancy but may be initiated postpartum; beta-blockers and hydralazine/isosorbide dinitrate are preferred during pregnancy.
Non-pharmacologic interventions are essential adjuncts to GDMT in heart failure management.
Structured exercise training or regular physical activity for all eligible patients is recommended, with the goal of improving functional status and quality of life.
Exercise training reduces heart failure hospitalizations and improves quality of life, with the greatest evidence in HFrEF but also meaningful benefit in HFpEF.
Dietary modification, including sodium restriction and weight management, is recommended for symptom control and functional improvement, especially in patients with obesity.
Devices, including cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillators (ICDs), are indicated in select patients with HFrEF to further reduce morbidity and mortality.
Cardiac resynchronization therapy (CRT) is recommended for patients with LVEF ≤35% and QRS duration ≥150 ms with left bundle branch block morphology, while ICDs are indicated for primary prevention of sudden cardiac death in patients with LVEF ≤35% despite at least three months of optimal GDMT.
The integration of these non-pharmacologic and device-based strategies with pharmacologic therapy, is fundamental to optimizing outcomes in heart failure.
All eligible patients with heart failure should receive a combination of ARNI, evidence-based beta-blocker, MRA, and SGLT2 inhibitor, with rapid initiation and titration to target or maximally tolerated doses, unless contraindicated.
Adjunctive therapies, non-pharmacologic interventions, and device therapy should be individualized based on phenotype, comorbidities, and patient preferences.